Karen H. Antman - Concepedia

Author

Karen H. Antman

Also Known As

Antman, Karen, J S Abrams, K Antman, K H Antman, K. ANTMAN, K. Antman, K. H. Antman, K.H Antman, K.H. ANTMAN, K.H. Antman

189

Publications

12.3K

Citations

H-Index

157

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Columbia University Brigham and Women's Hospital Boston University

About

Karen H. Antman is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	59	4.4K
2	Health Sciences	16	18	2K
3	Education	3	3	200
4	Nursing	3	3	45
5	Language Studies	1	1	198

Karen H. Antman

102

Publications

9.1K

Citations

H-Index

Page 1

	Year	Citations
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Karen H. Antman, John Crowley, S P Balcerzak, Journal of Clinical Oncology	1993	477
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. T. Frank, Susan Manley, O. I. Olopade, Journal of Clinical Oncology	1998	462
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Lee M. Nadler, Philip Stashenko, Russell Hardy, PubMed ImmunologyPathologyAntibody 89ImmunotherapeuticsMetronomic Chemotherapy	1980	416
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Karen H. Antman, Lois Ayash, Anthony Elias, Journal of Clinical Oncology	1992	374
Introduction: The History of Arsenic Trioxide in Cancer Therapy Karen H. Antman The Oncologist ImmunohematologyMixed-phenotype Acute LeukemiaMyeloid NeoplasiaHematological MalignancyOncology	2001	358
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Karen H. Antman, Philip A. Rowlings, William P. Vaughan, Journal of Clinical Oncology	1997	327
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. Karen H. Antman, Richard J. Shemin, Louise Ryan, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyPleural EffusionCancer Registration	1988	293
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. David J. Sugarbaker, Gary M. Strauss, Thomas J. Lynch, Journal of Clinical Oncology	1993	246
The Role of Cytologic Evaluation of Pleural Fluid in the Diagnosis of Malignant Mesothelioma Andrew A. Renshaw, Barbara R. Dean, Edmund S. Cibas, CHEST Journal	1997	229
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. Charles Hesdorffer, Janet Ayello, Maureen Ward, Journal of Clinical Oncology	1998	217

Page 1